Sign in
Taking people in South KoreaPhase 2/3

Testing JX10 in People With Stroke Who Arrive Late for Care

Tests JX10 against placebo in adults with stroke arriving late.

Key facts

Who runs it
Corxel Pharmaceuticals
Where
Seoul, South KoreaSee the siteAlso in 20 other countries, 100 sites
Trial code
Registry title
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Status
Recruiting
Phase
Phase 2/3
People taking part
740 people, planned
Started
15 May 2025
Expected to end
31 Dec 2029
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • JX10
  • Placebo
Record updated
21 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had an acute ischemic stroke (a stroke caused by a blocked brain artery) and reach care 4.5 to 24 hours after it began. It tests JX10 against a placebo.

Age
18 to 90 years old.
Sex
All sexes can join.
Disease stage
Acute ischemic stroke with a blocked large brain artery that causes symptoms, brain tissue that can still be saved on imaging, and a stroke severity score (NIHSS) of 5 or more.

Main reasons for not taking part

  • Large area of dead brain tissue (core infarction), or blockage in more than 1 area of the brain's blood supply
  • Bleeding in or outside the brain, a brain tumor (except a small meningioma), or an arteriovenous malformation
  • Active bleeding, bleeding disorder or high risk of major bleeding
  • Severe high blood pressure that cannot be controlled (systolic 185 mmHg or more, or diastolic 110 mmHg or more)
  • Major trauma, surgery or invasive procedures

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age ≥ 18 and ≤ 90 years old
  • Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA)
  • Radiographic evidence of salvageable tissue
  • Pre-treatment score of NIHSS ≥ 5

Who cannot take part

  • Major trauma, surgery, or invasive procedures
  • Radiographic findings pre-randomization of any of the following:; Large core infarction, or; Occlusion in more than 1 vascular territory, or; Significant mass effect or clinically significant cerebral edema, or; Evidence of acute intracranial or extracranial hemorrhage, intracranial tumor (except small meningioma), neoplasm, or arteriovenous malformation), or; Clinical history, past imaging, or clinical judgement suggests that the intracranial occlusion is chronic
  • Medical history or active clinically significant bleeding, lesions, or conditions (at the investigator's judgement) considered to be of significant risk for major bleeding
  • Severe, uncontrolled hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that cannot be controlled with antihypertensive therapy
  • Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations of this study
  • Known bleeding diathesis (hereditary or acquired) or any significant coagulopathy. Specifically, platelet count < 100,000/μL, international normalized ratio > 1.7, aPTT > 40 seconds, or prothrombin time > 15 seconds
  • Pre-treatment blood glucose > 400 mg/dL (22.20 mmol/L) or Pre-treatment blood glucose < 50 mg/dL (2.78 mmol/L) unless it is corrected prior to study treatment administration. Participants with subsequently normalized blood glucose levels may be considered for inclusion, per Investigator judgement

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 90 years old?

Where in South Korea

Also in 20 other countries, 100 sites

  • SeoulHospital not named in the registryContact: Study DirectorTaking people

About the trial

What the trial wants to find out

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours.

Read full original descriptionShow less

The main question the study aims to answer are:

1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS.

During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

The 5 groups in the trial

  • Part 1 - JX10 (1mg/kg)Treatment being tested

    Treatment: JX10

  • Part 1 - JX10 (3mg/kg)Treatment being tested

    Treatment: JX10

  • Part 1 - PlaceboPlacebo, for comparison

    Treatment: Placebo

  • JX10 Part 2 - (1 or 3 mg/kg)Treatment being tested

    Treatment: JX10

  • Part 2 - PlaceboPlacebo, for comparison

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke With Late Presentations
Plain-language title
Testing JX10 in People With Stroke Who Arrive Late for CareGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06990867, who can take part
Record updated
21 September 2026